Vanguards of Health Care: Precision Cardiology With Cytokinetics
“Now we’re seeing how there are new medicines that act directly on the heart itself and less on downstream consequences of heart disease,” says Robert Blum, president and CEO of...
By Aditya Somani · Bloomberg
“Now we’re seeing how there are new medicines that act directly on the heart itself and less on downstream consequences of heart disease,” says Robert Blum, president and CEO of Cytokinetics. On this episode of Vanguards of Health Care, Blum speaks with Bloomberg Intelligence analyst Andrew Galler about Cytokinetics’ transition to a commercial-stage company following the approval of Myqorzo, its competitive positioning in the obstructive hypertrophic cardiomyopathy market, and its potential to d